Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DuraSTAR: Dostarlimab in Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer
NCT07740720Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Sep 2026
- Primary completion
- Dec 2029
01
Overview
Phase 3, open-label, single-arm trial of dostarlimab in rectal cancer, sponsored by GSK. Primary endpoint: Clinical Complete Response at 168 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
dostarlimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07740720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07740720.